Pharmacokinetics of clarithromycin in rats with acute renal failure induced by uranyl nitrate
β Scribed by Ae K. Lee; Joo H. Lee; Jong W. Kwon; Won B. Kim; Sang G. Kim; So H. Kim; Myung G. Lee
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 110 KB
- Volume
- 25
- Category
- Article
- ISSN
- 0142-2782
- DOI
- 10.1002/bdd.409
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
In rats pretreated with dexamethasone (an inducer of CYP3A1/2 in rats) and troleandomycin (an inhibitor of CYP3A1/2 in rats), the area under the plasma concentrationβtime curve from time zero to time infinity (AUC) values of clarithromycin were significantly smaller (365 compared with 600Β΅gmin/ml) and greater (1410 compared with 581Β΅g min/ml), respectively, than those in control rats. This indicated that clarithromycin was metabolized via CYP3A1/2 in rats. The expression of CYP3A1(23) increased in rats with acute renal failure induced by uranyl nitrate (rats with UβARF). Hence, it could be expected that AUC of clarithromycin could be smaller in rats with UβARF. However, after intravenous administration of clarithromycin at a dose of 20mg/kg, the AUC and timeβaveraged total body (Cl) and nonrenal (Cl~nr~) clearance values were comparable between the two groups of rats. The 9000 Γ g supernatant fraction of liver homogenates in rats with UβARF had comparable metabolic activities for clarithromycin compared with those in control rats, suggesting that the CYP3A isozyme responsible for metabolism of clarithromycin seemed not to be expressed considerably in the rats. This could explain the comparable AUC, Cl and Cl~nr~ values of clarithromycin between the two groups of rats. Copyright Β© 2004 John Wiley & Sons, Ltd.
π SIMILAR VOLUMES
The pharmacokinetic and pharmacodynamic differences of azosemide were investigated after intravenous (IV) and oral administration of azosemide, 10 mg kg -1 , to the control and uranyl nitrate-induced acute renal failure (U-ARF) rats. After IV administration, the plasma concentrations of azosemide we
To examine the mechanism accounting for the diverse alteration of hepatic metabolism of CYP3A substrates observed with renal function being severely impaired, the hepatic drug metabolizing activity was evaluated using liver microsomes prepared from rats with glycerol-induced acute renal failure (ARF